Publication List Dr S Rose Tayarani‐Binazir, KA, Jackson, MJ, Strang, I, Jairaj, M, Rose, S, Jenner, P (2012) Benserazide dosing regimen affects the response to L‐3,4‐dihydroxyphenylalanine in the 6‐hydroxydopamine‐lesioned rat. Behav Pharmacol 23(2): 126‐133. Papathanou, M, van der Laan, R, Jenner, P, Rose, S, McCreary, AC (2012) Levodopa infusion does not decrease the onset of abnormal involuntary movements in Parkinsonian rats. Mov Disord. Long, P, Samnakay, P, Jenner, P, Rose, S (2012) A yeast two‐hybrid screen reveals that osteopontin associates with MAP1A and MAP1B in addition to other proteins linked to microtubule stability, apoptosis and protein degradation in the human brain. Eur J Neurosci 36(6): 2733‐2742. Iravani, MM, Sadeghian, M, Leung, CC, Jenner, P, Rose, S (2012) Lipopolysaccharide‐induced nigral inflammation leads to increased IL‐1beta tissue content and expression of astrocytic glial cell line‐
derived neurotrophic factor. Neurosci Lett 510(2): 138‐142. Iglesias‐Gonzalez, J, Sanchez‐Iglesias, S, Mendez‐Alvarez, E, Rose, S, Hikima, A, Jenner, P, Soto‐Otero, R (2012) Differential toxicity of 6‐hydroxydopamine in SH‐SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase. Neurochem Res 37(10): 2150‐2160. Papathanou, M, Rose, S, McCreary, A, Jenner, P (2011) Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats. Eur J Neurosci 33(12): 2247‐2254. Hansard, MJ, Jackson, MJ, Smith, LA, Rose, S, Jenner, P (2011) A major metabolite of bupropion reverses motor deficits in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets. Behav Pharmacol 22(3): 269‐274. Brzozowski, MJ, Alcantara, SL, Iravani, MM, Rose, S, Jenner, P (2011) The effect of nNOS inhibitors on toxin‐induced cell death in dopaminergic cell lines depends on the extent of enzyme expression. Brain Res 1404: 21‐30. Zhou, T, Hider, RC, Jenner, P, Campbell, B, Hobbs, CJ, Rose, S, Jairaj, M, Tayarani‐Binazir, KA, Syme, A (2010) Design, synthesis and biological evaluation of L‐dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease. Eur J Med Chem 45(9): 4035‐4042. Zeng, BY, Iravani, MM, Jackson, MJ, Rose, S, Parent, A, Jenner, P (2010a) Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol Dis 40(3): 599‐607. Zeng, BY, Balfour, RH, Jackson, MJ, Rose, S, Jenner, P (2010b) Expression of catechol‐O‐
methyltransferase in the brain and periphery of normal and MPTP‐treated common marmosets. J Neural Transm 117(1): 45‐51. Tayarani‐Binazir, KA, Jackson, MJ, Rose, S, Olanow, CW, Jenner, P (2010a) Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets. Mov Disord 25(3): 377‐384. Tayarani‐Binazir, KA, Jackson, MJ, Fisher, R, Zoubiane, G, Rose, S, Jenner, P (2010b) The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L‐DOPA in the MPTP‐treated common marmoset. Eur J Pharmacol 635(1‐3): 109‐116. Tayarani‐Binazir, K, Jackson, MJ, Rose, S, McCreary, AC, Jenner, P (2010c) The partial dopamine agonist pardoprunox (SLV308) administered in combination with l‐dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Exp Neurol 226(2): 320‐327. Stockwell, KA, Scheller, DK, Smith, LA, Rose, S, Iravani, MM, Jackson, MJ, Jenner, P (2010) Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L‐
DOPA in MPTP‐treated common marmosets. Exp Neurol 221(1): 79‐85. Jones, CA, Johnston, LC, Jackson, MJ, Smith, LA, van Scharrenburg, G, Rose, S, Jenner, PG, McCreary, AC (2010) An in vivo pharmacological evaluation of pardoprunox (SLV308)‐‐a novel combined dopamine D(2)/D(3) receptor partial agonist and 5‐HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. Eur Neuropsychopharmacol 20(8): 582‐593. Johnston, LC, Jackson, MJ, Rose, S, McCreary, AC, Jenner, P (2010) Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets. Mov Disord 25(13): 2059‐2066. Iczkiewicz, J, Broom, L, Cooper, JD, Wong, AM, Rose, S, Jenner, P (2010) The RGD‐containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra. J Neurochem 114(6): 1792‐1804. Bukhatwa, S, Zeng, BY, Rose, S, Jenner, P (2010a) A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Brain Res 1326: 174‐183. Bukhatwa, S, Zeng, BY, Rose, S, Jenner, P (2010b) The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain. Brain Res 1354: 236‐242. Stockwell, KA, Scheller, D, Rose, S, Jackson, MJ, Tayarani‐Binazir, K, Iravani, MM, Smith, LA, Olanow, CW, Jenner, P (2009) Continuous administration of rotigotine to MPTP‐treated common marmosets enhances anti‐parkinsonian activity and reduces dyskinesia induction. Exp Neurol 219(2): 533‐542. Bukhatwa, S, Iravani, MM, Zeng, BY, Cooper, JD, Rose, S, Jenner, P (2009) An immunohistochemical and stereological analysis of PSI‐induced nigral neuronal degeneration in the rat. J Neurochem 109(1): 52‐59. Stockwell, KA, Virley, DJ, Perren, M, Iravani, MM, Jackson, MJ, Rose, S, Jenner, P (2008) Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP‐treated common marmosets. Exp Neurol 211(1): 172‐179. Iravani, MM, Sadeghian, M, Leung, CC, Tel, BC, Rose, S, Schapira, AH, Jenner, P (2008) Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide‐induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol 212(2): 522‐531. Zubair, M, Jackson, MJ, Tayarani‐Binazir, K, Stockwell, KA, Smith, LA, Rose, S, Olanow, W, Jenner, P (2007) The administration of entacapone prevents L‐dopa‐induced dyskinesia when added to dopamine agonist therapy in MPTP‐treated primates. Exp Neurol 208(2): 177‐184. Rose, S, Scheller, DK, Breidenbach, A, Smith, L, Jackson, M, Stockwell, K, Jenner, P (2007a) Plasma levels of rotigotine and the reversal of motor deficits in MPTP‐treated primates. Behav Pharmacol 18(2): 155‐160. Rose, S, Ramsay Croft, N, Jenner, P (2007b) The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l‐dopa in unilaterally 6‐OHDA‐lesioned rats. Brain Res 1133(1): 110‐114. Katzenschlager, R, Jackson, MJ, Rose, S, Stockwell, K, Tayarani‐Binazir, KA, Zubair, M, Smith, LA, Jenner, P, Lees, AJ (2007) Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐
inhibiting factor in MPTP‐treated common marmosets. Mov Disord 22(5): 715‐719. Jackson, MJ, Smith, LA, Al‐Barghouthy, G, Rose, S, Jenner, P (2007) Decreased expression of l‐dopa‐
induced dyskinesia by switching to ropinirole in MPTP‐treated common marmosets. Exp Neurol 204(1): 162‐170. Iczkiewicz, J, Rose, S, Jenner, P (2007) Osteopontin expression in activated glial cells following mechanical‐ or toxin‐induced nigral dopaminergic cell loss. Exp Neurol 207(1): 95‐106. Hurley, MJ, Patel, PH, Jackson, MJ, Smith, LA, Rose, S, Jenner, P (2007) Striatal leucine‐rich repeat kinase 2 mRNA is increased in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned common marmosets (Callithrix jacchus) with L‐3, 4‐dihydroxyphenylalanine methyl ester‐induced dyskinesia. Eur J Neurosci 26(1): 171‐177. Zeng, BY, Iravani, MM, Lin, ST, Irifune, M, Kuoppamaki, M, Al‐Barghouthy, G, Smith, L, Jackson, MJ, Rose, S, Medhurst, AD, Jenner, P (2006a) MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome. Eur J Neurosci 23(7): 1766‐1774. Zeng, BY, Bukhatwa, S, Hikima, A, Rose, S, Jenner, P (2006b) Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol 60(2): 248‐252. Smith, LA, Jackson, MJ, Johnston, L, Kuoppamaki, M, Rose, S, Al‐Barghouthy, G, Del Signore, S, Jenner, P (2006) Switching from levodopa to the long‐acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP‐treated primates. Clin Neuropharmacol 29(3): 112‐125. Rose, S, Jackson, MJ, Smith, LA, Stockwell, K, Johnson, L, Carminati, P, Jenner, P (2006) The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L‐DOPA in MPTP treated common marmosets. Eur J Pharmacol 546(1‐3): 82‐87. Iravani, MM, Haddon, CO, Rose, S, Jenner, P (2006) 3‐Nitrotyrosine‐dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor. Brain Res 1067(1): 256‐262. Iczkiewicz, J, Jackson, MJ, Smith, LA, Rose, S, Jenner, P (2006) Osteopontin expression in substantia nigra in MPTP‐treated primates and in Parkinson's disease. Brain Res 1118(1): 239‐250. Carotti, A, Altomare, C, Catto, M, Gnerre, C, Summo, L, De Marco, A, Rose, S, Jenner, P, Testa, B (2006) Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7‐
substituted coumarins. Chem Biodivers 3(2): 134‐149. Zeng, BY, Medhurst, AD, Jackson, M, Rose, S, Jenner, P (2005) Proteasomal activity in brain differs between species and brain regions and changes with age. Mech Ageing Dev 126(6‐7): 760‐766. Smith, LA, Jackson, MJ, Al‐Barghouthy, G, Rose, S, Kuoppamaki, M, Olanow, W, Jenner, P (2005) Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naive primates. Mov Disord 20(3): 306‐314. Iravani, MM, Leung, CC, Sadeghian, M, Haddon, CO, Rose, S, Jenner, P (2005) The acute and the long‐
term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 22(2): 317‐330. Iczkiewicz, J, Rose, S, Jenner, P (2005) Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. Eur J Neurosci 21(7): 1911‐1920. Hurley, MJ, Jackson, MJ, Smith, LA, Rose, S, Jenner, P (2005) Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP‐treated common marmosets. Eur J Neurosci 21(12): 3240‐3250. Abd El Mohsen, MM, Iravani, MM, Spencer, JP, Rose, S, Fahim, AT, Motawi, TM, Ismail, NA, Jenner, P (2005) Age‐associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants. Biochem Biophys Res Commun 336(2): 386‐391. Zeng, BY, Heales, SJ, Canevari, L, Rose, S, Jenner, P (2004) Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase‐deficient mice. Exp Neurol 190(2): 515‐524. Whitehead, KJ, Rose, S, Jenner, P (2004) Halothane anesthesia affects NMDA‐stimulated cholinergic and GABAergic modulation of striatal dopamine efflux and metabolism in the rat in vivo. Neurochem Res 29(4): 835‐842. Iravani, MM, Liu, L, Rose, S, Jenner, P (2004) Role of inducible nitric oxide synthase in N‐methyl‐d‐
aspartic acid‐induced strio‐nigral degeneration. Brain Res 1029(1): 103‐113. Iczkiewicz, J, Rose, S, Jenner, P (2004) Osteopontin (Eta‐1) is present in the rat basal ganglia. Brain Res Mol Brain Res 132(1): 64‐72. Treseder, SA, Rose, S, Summo, L, Jenner, P (2003) Commonly used L‐amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat. J Neural Transm 110(3): 229‐238. Silva, MT, Rose, S, Hindmarsh, JG, Jenner, P (2003) Inhibition of neuronal nitric oxide synthase increases dopamine efflux from rat striatum. J Neural Transm 110(4): 353‐362. Schwarz, MJ, Houghton, PJ, Rose, S, Jenner, P, Lees, AD (2003) Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism. Pharmacol Biochem Behav 75(3): 627‐633. Gilbert, EA, Edwards, RJ, Boobis, AR, Rose, S, Jenner, P (2003) Differential expression of cytochrome P450 enzymes in cultured and intact foetal rat ventral mesencephalon. J Neural Transm 110(10): 1091‐1101. Cannizzaro, C, Tel, BC, Rose, S, Zeng, BY, Jenner, P (2003) Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Brain Res Mol Brain Res 110(2): 169‐176. Zeng, BY, Dass, B, Owen, A, Rose, S, Cannizzaro, C, Tel, BC, Jenner, P (2002) 6‐Hydroxydopamine lesioning differentially affects alpha‐synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats. Neurosci Lett 322(1): 33‐36. Tel, BC, Zeng, BY, Cannizzaro, C, Pearce, RK, Rose, S, Jenner, P (2002) Alterations in striatal neuropeptide mRNA produced by repeated administration of L‐DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP‐treated common marmosets. Neuroscience 115(4): 1047‐1058. Smith, LA, Tel, BC, Jackson, MJ, Hansard, MJ, Braceras, R, Bonhomme, C, Chezaubernard, C, Del Signore, S, Rose, S, Jenner, P (2002) Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: a behavioural and biochemical investigation. Mov Disord 17(5): 887‐901. Iravani, MM, Kashefi, K, Mander, P, Rose, S, Jenner, P (2002) Involvement of inducible nitric oxide synthase in inflammation‐induced dopaminergic neurodegeneration. Neuroscience 110(1): 49‐58. Abd El Mohsen, MM, Kuhnle, G, Rechner, AR, Schroeter, H, Rose, S, Jenner, P, Rice‐Evans, CA (2002) Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med 33(12): 1693‐1702. Whitehead, KJ, Rose, S, Jenner, P (2001) Involvement of intrinsic cholinergic and GABAergic innervation in the effect of NMDA on striatal dopamine efflux and metabolism as assessed by microdialysis studies in freely moving rats. Eur J Neurosci 14(5): 851‐860. Treseder, SA, Rose, S, Jenner, P (2001) The central aromatic amino acid DOPA decarboxylase inhibitor, NSD‐1015, does not inhibit L‐DOPA‐induced circling in unilateral 6‐OHDA‐lesioned‐rats. Eur J Neurosci 13(1): 162‐170. Liu, ZD, Lockwood, M, Rose, S, Theobald, AE, Hider, RC (2001) Structure‐activity investigation of the inhibition of 3‐hydroxypyridin‐4‐ones on mammalian tyrosine hydroxylase. Biochem Pharmacol 61(3): 285‐290. Ferger, B, Themann, C, Rose, S, Halliwell, B, Jenner, P (2001a) 6‐hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: implication of peroxynitrite formation. J Neurochem 78(3): 509‐514. Ferger, B, Rose, S, Jenner, A, Halliwell, B, Jenner, P (2001b) 6‐hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum. Neuroreport 12(6): 1155‐1159. Riedl, AG, Watts, PM, Douek, DC, Edwards, RJ, Boobis, AR, Rose, S, Jenner, P (2000) Expression and distribution of CYP2C enzymes in rat basal ganglia. Synapse 38(4): 392‐402. Zeng, BY, Dass, B, Owen, A, Rose, S, Cannizzaro, C, Tel, BC, Jenner, P (1999) Chronic L‐DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6‐hydroxydopamine‐
lesioned rats. Neurosci Lett 276(2): 71‐74. Rose, S, MacKenzie, GM, Jenner, P (1999a) Nitric oxide and basal ganglia degeneration. Adv Neurol 80: 247‐257. Rose, S, Hindmarsh, JG, Jenner, P (1999b) Neuronal nitric oxide synthase inhibition reduces MPP+‐
evoked hydroxyl radical formation but not dopamine efflux in rat striatum. J Neural Transm 106(5‐6): 477‐486. Silva, MT, Rose, S, Hindmarsh, JG, Jenner, P, Marsden, CD (1998) L‐arginine produces NO‐
independent increases in dopamine efflux in rat striatum. Neuroreport 9(1): 149‐152. Rose, S, Hindmarsh, JG, Collins, P, Jenner, P (1997) The effect of fenfluramine dosage regimen and reduced food intake on levels of 5‐HT in rat brain. J Neural Transm 104(11‐12): 1339‐1351. Rose, S, Hunt, S, Collins, P, Hindmarsh, JG, Jenner, P (1996) Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats. Neurodegeneration 5(2): 145‐152. Fernandez, A, de Ceballos, ML, Rose, S, Jenner, P, Marsden, CD (1996) Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease. Brain 119 ( Pt 3): 823‐830. Silva, MT, Rose, S, Hindmarsh, JG, Aislaitner, G, Gorrod, JW, Moore, PK, Jenner, P, Marsden, CD (1995) Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7‐nitro indazole. Br J Pharmacol 114(2): 257‐258. Brunner‐Guenat, M, Carrupt, PA, Lisa, G, Testa, B, Rose, S, Thomas, K, Jenner, P, Ventura, P (1995) Esters of L‐dopa: structure‐hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism. J Pharm Pharmacol 47(10): 861‐869. Rose, S, Jenner, P, Marsden, CD (1994a) Chronic administration does not alter the accumulation of L‐
dopa into muscle. Mov Disord 9(2): 167‐172. Rose, S, Hindmarsh, JG, Steiger, MJ, Bhatt, M, Quinn, NP, Jenner, P, Marsden, CD (1994b) Plasma HVA levels following debrisoquine administration do not reflect cerebral dopamine loss in early Parkinson's disease. Clin Neuropharmacol 17(3): 260‐269. MacKenzie, GM, Rose, S, Bland‐Ward, PA, Moore, PK, Jenner, P, Marsden, CD (1994) Time course of inhibition of brain nitric oxide synthase by 7‐nitro indazole. Neuroreport 5(15): 1993‐1996. Rose, S, Nomoto, M, Jackson, EA, Gibb, WR, Jaehnig, P, Jenner, P, Marsden, CD (1993a) Age‐related effects of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 230(2): 177‐185. Rose, S, Jenner, P, Marsden, CD (1993b) Chronic administration does not alter the pharmacokinetic profile of L‐dopa in the rat. J Pharm Pharmacol 45(8): 725‐730. Thomas, KL, Rose, S, Jenner, P, Marsden, CD (1992a) Dissociation of the striatal D‐2 dopamine receptor from adenylyl cyclase following 6‐hydroxydopamine‐induced denervation. Biochem Pharmacol 44(1): 73‐82. Thomas, KL, Rose, S, Jenner, P, Marsden, CD (1992b) Acute reserpine treatment induces down regulation of D‐1 dopamine receptor associated adenylyl cyclase activity in rat striatum. Biochem Pharmacol 44(1): 83‐91. Taylor, MD, De Ceballos, ML, Rose, S, Jenner, P, Marsden, CD (1992) Effects of a unilateral 6‐
hydroxydopamine lesion and prolonged L‐3,4‐dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur J Pharmacol 219(2): 183‐192. Taylor, MD, de Ceballos, ML, Rose, S, Chong, PN, Jenner, P, Marsden, CD (1991) Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP. J Neural Transm Park Dis Dement Sect 3(2): 99‐108. Rose, S, Jenner, P, Marsden, CD (1991) Peripheral pharmacokinetic handling and metabolism of L‐
dopa in the rat: the effect of route of administration and carbidopa pretreatment. J Pharm Pharmacol 43(5): 325‐330. Rose, S, Nomoto, M, Jackson, EA, Gibb, WR, Jenner, P, Marsden, CD (1990) 1‐Methyl‐4‐(2'‐
methylphenyl)‐1,2,3,6‐tetrahydropyridine (2'‐methyl‐MPTP) is less neurotoxic than MPTP in the common marmoset. Eur J Pharmacol 181(1‐2): 97‐103. Ueki, A, Chong, PN, Albanese, A, Rose, S, Chivers, JK, Jenner, P, Marsden, CD (1989) Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. Neuropharmacology 28(10): 1089‐
1097. Rose, S, Thomas, K, Jenner, P, Marsden, CD (1989a) Fluctuations in response to L‐dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover. Br J Pharmacol 98 Suppl: 816P. Rose, S, Nomoto, M, Kelly, E, Kilpatrick, G, Jenner, P, Marsden, CD (1989b) Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci Lett 101(3): 305‐310. Rose, S, Nomoto, M, Jenner, P, Marsden, CD (1989c) Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. Biochem Pharmacol 38(21): 3677‐3681. Rose, S, Nomoto, M, Jackson, EA, Gibb, WR, Jenner, P, Marsden, CD (1989d) Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP‐treated common marmosets. Neuropharmacology 28(11): 1211‐1216. Taquet, H, Nomoto, M, Rose, S, Jenner, P, Javoy‐Agid, F, Mauborgne, A, Benoliel, JJ, Marsden, CD, Legrand, JC, Agid, Y, et al. (1988) Levels of Met‐enkephalin, Leu‐enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1‐methyl‐4‐phenyl‐
1,2,3,6,‐tetrahydropyridine treatment. Neuropeptides 12(3): 105‐110. Rose, S, Jenner, P, Marsden, CD (1988) The effect of carbidopa on plasma and muscle levels of L‐
dopa, dopamine, and their metabolites following L‐dopa administration to rats. Mov Disord 3(2): 117‐125. Weller, ME, Rose, S, Jenner, P, Marsden, CD (1987) In vitro characterisation of dopamine receptors in the superior colliculus of the rat. Neuropharmacology 26(4): 347‐354. Stewart, B, Rose, S, Jenner, P, Marsden, CD (1987) Pilocarpine‐induced purposeless chewing behaviour in rats is dependent on intact central stores of 5‐HT. Eur J Pharmacol 142(1): 173‐176. Jenner, P, Rose, S, Nomoto, M, Marsden, CD (1987) MPTP‐induced parkinsonism in the common marmoset: behavioral and biochemical effects. Adv Neurol 45: 183‐186. Jenner, P, Taquet, H, Mauborgne, A, Benoliel, JT, Cesselin, F, Rose, S, Javoy‐Agid, F, Agid, Y, Marsden, CD (1986) Lack of change in basal ganglia neuropeptide content following subacute 1‐methyl‐4‐
phenyl‐1,2,3,6‐tetrahydropyridine treatment of the common marmoset. J Neurochem 47(5): 1548‐
1551. Garvey, J, Petersen, M, Waters, CM, Rose, SP, Hunt, S, Briggs, R, Jenner, P, Marsden, CD (1986) Administration of MPTP to the common marmoset does not alter cortical cholinergic function. Mov Disord 1(2): 129‐134. de Ceballos, ML, Baker, M, Rose, S, Jenner, P, Marsden, CD (1986) Do enkephalins in basal ganglia mediate a physiological motor rest mechanism? Mov Disord 1(4): 223‐233. Jenner, P, Rupniak, NM, Rose, S, Kelly, E, Kilpatrick, G, Lees, A, Marsden, CD (1984) 1‐Methyl‐4‐
phenyl‐1,2,3,6‐tetrahydropyridine‐induced parkinsonism in the common marmoset. Neurosci Lett 50(1‐3): 85‐90.